Skye Bioscience Inc
NASDAQ:SKYE
Operating Margin
Skye Bioscience Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
Skye Bioscience Inc
NASDAQ:SKYE
|
84m USD | N/A | ||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
||
US |
Abbvie Inc
NYSE:ABBV
|
309.5B USD |
28%
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
140.9B USD |
19%
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
112B USD |
38%
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.6B USD |
40%
|
||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
CSL Ltd
ASX:CSL
|
137.8B AUD |
26%
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.7B USD |
30%
|
||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
argenx SE
XBRU:ARGX
|
38.5B EUR |
-15%
|
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Skye Bioscience Inc's most recent financial statements, the company has Operating Margin of 0%.